indications of the approximate time requested to make their presentation. The agenda for the public webinar will be made available on the Internet at http://www.fda.gov/Drugs/NewsEvents/ucm466461.htm.

III. Transcripts

Please be advised that as soon as a webinar transcript is available, FDA will post it at http://www.fda.gov/Drugs/NewsEvents/ucm466461.htm.

Dated: October 29, 2015.  
Leslie Kux,  
Associate Commissioner for Policy.  
[FR Doc. 2015–27953 Filed 11–2–15; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2015–N–0001]

Science Board to the Food and Drug Administration Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Science Board to the Food and Drug Administration (Science Board).

General Function of the Committee: The Science Board provides advice to the Commissioner of Food and Drugs and other appropriate officials on specific, complex scientific and technical issues important to the FDA and its mission, including emerging issues within the scientific community. Additionally, the Science Board provides advice to the Agency on keeping pace with technical and scientific developments including in regulatory science, input into the Agency’s research agenda and on upgrading its scientific and research facilities and training opportunities. It will also provide, where requested, expert review of Agency sponsored intramural and extramural scientific research programs.

Date and Time: The meeting will be held on November 18, 2015, from 9 a.m. until 4 p.m.

Location: Food and Drug Administration, White Oak 31, Rm. 1503, Section A, 10903 New Hampshire Ave., Silver Spring, MD 20903. For the public conduct during advisory committee meetings. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Rakesh Raghuwanshi at least 7 days in advance of the meeting.

Persons attending FDA’s advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/default.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Jill Hartzler Warner,  
Associate Commissioner for Special Medical Programs.  
[FR Doc. 2015–27957 Filed 11–2–15; 8:45 am]

BILLING CODE 4164–01–P